362 related articles for article (PubMed ID: 8428362)
1. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
2. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Hanlon MH; Ferone R
Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
[TBL] [Abstract][Full Text] [Related]
3. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
6. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.
Matherly LH; Czajkowski CA; Muench SP; Psiakis JT
Cancer Res; 1990 Jun; 50(11):3262-9. PubMed ID: 2139802
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid.
Smith GK; Amyx H; Boytos CM; Duch DS; Ferone R; Wilson HR
Cancer Res; 1995 Dec; 55(24):6117-25. PubMed ID: 8521402
[TBL] [Abstract][Full Text] [Related]
8. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
9. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
10. Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates.
Houghton PJ; Rahman A; Will CL; Dolnick BJ; Houghton JA
Cancer Res; 1992 Feb; 52(3):558-65. PubMed ID: 1732043
[TBL] [Abstract][Full Text] [Related]
11. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
12. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.
Jiang L; Lee PC; White J; Rathod PK
Antimicrob Agents Chemother; 2000 Apr; 44(4):1047-50. PubMed ID: 10722510
[TBL] [Abstract][Full Text] [Related]
14. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.
Westerhof GR; Jansen G; van Emmerik N; Kathmann I; Rijksen G; Jackman AL; Schornagel JH
Cancer Res; 1991 Oct; 51(20):5507-13. PubMed ID: 1655252
[TBL] [Abstract][Full Text] [Related]
15. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
Chello PL; McQueen CA; DeAngelis LM; Bertino JR
Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
17. Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.
Fry DW; Besserer JA; Boritzki TJ
Cancer Res; 1984 Aug; 44(8):3366-70. PubMed ID: 6547636
[TBL] [Abstract][Full Text] [Related]
18. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
19. Role of methylenetetrahydrofolate depletion in methotrexate-mediated intracellular thymidylate synthesis inhibition in cultured L1210 cells.
Bunni M; Doig MT; Donato H; Kesavan V; Priest DG
Cancer Res; 1988 Jun; 48(12):3398-404. PubMed ID: 3370638
[TBL] [Abstract][Full Text] [Related]
20. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
